Increased CSF DOPA Decarboxylase Correlates with Lower DaT‐SPECT Binding: Analyses in Biopark and PPMI Cohorts

Background Recent studies identified increased cerebrospinal fluid (CSF) DOPA decarboxylase (DDC) as a promising biomarker for parkinsonian disorders, suggesting a compensation to dying dopaminergic neurons. A correlation with 123I‐FP‐CIT‐SPECT (DaT‐SPECT) imaging could shed light on this link. Obje...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 39; no. 10; pp. 1881 - 1885
Main Authors Khosousi, Shervin, Sturchio, Andrea, Appleton, Ellen, Paslawski, Wojciech, Ta, Michael, Nalls, Michael, Singleton, Andrew B., Iwaki, Hirotaka, Svenningsson, Per
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.10.2024
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Recent studies identified increased cerebrospinal fluid (CSF) DOPA decarboxylase (DDC) as a promising biomarker for parkinsonian disorders, suggesting a compensation to dying dopaminergic neurons. A correlation with 123I‐FP‐CIT‐SPECT (DaT‐SPECT) imaging could shed light on this link. Objective The objective is to assess the relationship between CSF DDC levels and DaT‐SPECT binding values. Methods A total of 51 and 72 Parkinson's disease (PD) subjects with available DaT‐SPECT and CSF DDC levels were selected from the PPMI and Biopark cohorts, respectively. DDC levels were analyzed using proximity extension assay and correlated with DaT‐SPECT striatal binding ratios (SBR). All analyses were corrected for age and sex. Results CSF DDC levels in PD patients correlated negatively with DaT‐SPECT SBR in both putamen and caudate nucleus. Additionally, SBR decreased with increased DDC levels over time in PD patients. Conclusion CSF DDC levels negatively correlate with DaT‐SPECT SBR in levodopa‐treated PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Bibliography:The work was funded by Stockholm City Council, SciLife postdoctoral program, Knut and Alice Wallenberg Foundation. This work was supported in part by the Intramural Research Program of the National Institute on Aging (NIA), and the Center for Alzheimer's and Related Dementias (CARD), within the Intramural Research Program of the National Institute on Aging and the National Institute of Neurological Disorders and Stroke (AG000546). Parkinson Progression Marker Initiative (PPMI) is sponsored by The Michael J. Fox Foundation for Parkinson's Research and supported by a consortium of scientific partners. Funding: PPMI—a public‐private partnership—is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, AbbVie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol‐Myers Squibb, Calico Labs, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics. The Parkinson's Disease Biomarker Program consortium is supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health.
A.S. cofounded REGAIN Therapeutics. M.N. and H.I.'s participation in this project was part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. M.N. also currently serves on the scientific advisory board for Character Bio Inc and is a scientific founder at Neuron23 and owns stock. A.B.S. serves on the scientific advisory board of Cajal Neuroscience. All other authors report no conflicts of interest.
Shervin Khosousi and Andrea Sturchio contributed equally.
Funding agencies
Potential conflict of interest
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0885-3185
1531-8257
1531-8257
DOI:10.1002/mds.29835